Citations

Clear

39 citation(s) found for "Dubinsky, Marla".

S1081 Effect of Upadacitinib Treatment on Hematological Parameters in Patients With Moderate to Severe Active Crohn’s Disease or Ulcerative Colitis: Pooled Analysis of Phase 3 Induction and Maintenance Studies
Dubinsky, Marla, Ha, Christina , Melmed, Gil , Irving, Peter M., Anyanwu, Samuel, Dubcenco, Elena, Aponte, Fernando, Shah, Isheeta, Wang, Tao , Suravaram, Smitha, Melmed, Gil Y , Regueiro, Miguel , Armuzzi, Alessandro , Shah, Isheeta, Palac, Hannah , Rubin, David T.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S765-S766

10.14309/01.ajg.0001033692.25720.00 Get It

Durable Immune Response and Long-term Efficacy of COVID-19 Vaccination in Children With Inflammatory Bowel Disease
Kastl, Arthur , Weaver, Kimberly N. , Zhang, Xian , Strople, Jennifer , Adler, Jeremy, Dubinsky, Marla C. , Bousvaros, Athos, Watkins, Runa , Dai, Xiangfeng , Chen, Wenli , Higgins, Peter D R , Bewtra, Meenakshi , Bellaguarda, Emanuelle, Chun, Kelly , Zikry, Michael, Bastidas, Monique , Firestine, Ann M. , Craig, Riley, Boccieri, Margie , Long, Millie D. , Kastl, Arthur J , Farraye, Francis A , Long, Millie D , Kappelman, Michael D , Brenner, Erica J. , Adler, Jeremy, Cross, Raymond K. , Ungaro, Ryan C. , Farraye, Francis A. , Kappelman, Michael D.

Mayo Clinic

Inflammatory Bowel Diseases | October 16, 2024 | Volume: 31 | Issue: 7 | Pages: 1797-1805

10.1093/ibd/izae225 | PMID 39412147 Get It

Abstract Background Children with inflammatory bowel disease (IBD) may have diminished serologic response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and increased risk for subsequent severe coronavirus disease 2019 (COVID-19) infection. We sought to describe outcomes among those who developed SARS-CoV-2 infection following vaccination, characterize SARS-CoV-2 antibodies 1 year post-vaccination, and identify factors associated with durable serologic response. Methods We recruited children with IBD who received ≥2 doses of SARS-CoV-2 vaccine and prospectively collected data on (1) demographics, IBD characteristics, and therapy and (2) SARS-CoV-2 vaccination, testing, and infection symptoms. Serum was obtained for measurement of anti-receptor-binding domain IgG antibodies following a 2-part immunization at 12 and 52 weeks. Results We enrolled 298 participants (mean age 11.9 ± 3.82, 50% female, 67% Crohn’s disease). Symptomatic COVID-19 infection after vaccination occurred in half of the participants, although only 2 (1%) required hospitalization. Anti-tumor necrosis factor alpha (TNF-α) was associated with higher likelihood of symptomatic COVID-19 infection, with an adjusted hazard ratio of 2.7 (95% CI, 1.5-5.0; P = .001). Nearly all participants (99%) had detectable antibody at Week 52. Children aged 1-5 years had lower 52-week antibody level compared to older children (P = .04), as did those on anti-TNF-α therapy (P = .007) and those who received only 2 vaccine doses prior to Week 52 (P < .001). Conclusions SARS-CoV-2 vaccination provides lasting serologic response and protection against severe COVID-19 for most children with IBD, despite the use of lower vaccine doses in younger children and wide-ranging classes of immunosuppressive therapies.
Risankizumab Is Effective for The Management of Crohn’s Disease of the Pouch
Kayal, Maia , Spencer, Elizabeth A. , Smyth, Matthew D. , Raffals, Laura E. , Qazi, Taha , Deepak, Parakkal , Beniwal‐Patel, Poonam , Chang, Shannon, Higgins, Peter , Cross, Raymond, Anderson, Chelsea , Long, Millie D. , Dubinsky, Marla C. , Raffals, Laura , Dubinsky, Marla , Kayal, Maia , Deepak, Parakkal , Qazi, Taha , Herfarth, Hans , Barnes, Edward L.

Mayo Clinic

Inflammatory Bowel Diseases | July 4, 2024 | Volume: 31 | Issue: 3 | Pages: 878-881

10.1093/ibd/izae164 | PMID 39038228 Get It

Lay Summary In this prospective, multicenter observational study of highly refractory patients with Crohn’s disease of the pouch, risankizumab achieved the primary outcome of clinical remission in 50% and the more stringent secondary outcome of antibiotic- and steroid-free remission in 30.8% at 12 weeks.
Humoral immune response and safety of SARS‐CoV‐2 vaccination in very early onset inflammatory bowel disease
Kastl, Arthur , Weaver, Kimberly N. , Zhang, Xian , Strople, Jennifer A., Adler, Jeremy, Kelsen, Judith R. , Dubinsky, Marla C. , Bousvaros, Athos, Watkins, Runa , Dai, Colin, Cross, Raymond, Higgins, Peter , Bewtra, Meenakshi , Bellaguarda, Emanuelle, Chun, Kelly , Zikry, Michael, Bastidas, Monique , Boccieri, Margie E., Firestine, Ann M. , Long, Millie D. , Adler, Jeremy, Ungaro, Ryan C. , Farraye, Francis A. , Boccieri, Margie , Kappelman, Michael D. , Adler, J

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | February 15, 2024 | Volume: 78 | Issue: 4 | Pages: 871-877

10.1002/jpn3.12142 | PMID 38356293 Get It

AbstractChildren with very early onset inflammatory bowel disease (VEO‐IBD) may respond differently to coronavirus disease 2019 (COVID‐19) immunization compared to healthy children or other patients with IBD. We recruited children with VEO‐IBD <6 years of age and younger following receipt of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccine. Demographics, IBD characteristics, medication use, adverse events (AEs) and IBD exacerbations were collected. Blood draws (optional) were obtained for measurement of antireceptor binding domain (RBD) IgG antibodies following vaccination. Of 41 participants, none required emergency department visit or hospitalization due to AE, and only one experienced IBD exacerbation. Detectable antibody was present in 19/19 participants who provided blood sample; 6/7 participants (86%) had durable humoral response 12 months postvaccination. Children with VEO‐IBD experience robust humoral immune response to COVID‐19 immunization. Severe AEs were rare. These findings provide reassurance that children with VEO‐IBD respond well and safely to SARS‐CoV‐2 vaccination.
P115 Ustekinumab in DEVELOP: A safety analysis from an Inflammatory Bowel Disease multicenter, prospective, long-term registry of paediatric patients
Koletzko, Sibylle , Veereman, Gigi , Hyams, Jeffrey S. , Dubinsky, Marla C. , Godwin, B, Busse, Christopher, Strauss, Richard E. , Wang, Y, Colletti, Richard B. , Kugathasan, S., Markowitz, James , Winter, Harland S. , Baldassano, Robert N. , Ruemmele, Frank, Faubion, William A. , Gold, B. D., Strauss, R, Volger, Sheri , Griffiths, Anne Marie , Escher, Johanna C. , Ruemmele, Frank M.

Mayo Clinic

Journal of Crohn's and Colitis | January 24, 2024 | Volume: 18 | Issue: Supplement_1 | Pages: i398-i399

10.1093/ecco-jcc/jjad212.0245 Get It

Abstract Background DEVELOP is a multi-center, global, prospective, observational, longitudinal registry of long-term safety of infliximab (and other treatments) in paediatric patients (pts) with inflammatory bowel disease (IBD) &lt;18 years (yrs) at diagnosis. Over the course of follow-up, many pts required changes in therapy. Ustekinumab (UST) is approved for treatment of Crohn’s disease (CD) in adults and is currently being evaluated for safety/efficacy in paediatric pts. This report focuses on assessment of safety of UST in paediatric pts with CD from DEVELOP. Methods Data included paediatric pts treated with UST from 31 May 2007 through 30 June 2022; data are collected every 6 months. The analyzed population included: all paediatric pts (all pts), pts weighing &lt;40kg (&lt;40kg group), and pts weighing ≥40kg (≥40kg group). Assessments included medical and treatment history, UST exposure, adverse events (AEs), serious AEs (SAEs), CD-related SAEs leading to hospitalization, IBD surgeries, serious and opportunistic infections, malignancies, and deaths. Results A total of 150 pts received UST (49.3% females); 31 in the &lt;40kg group and 119 in the ≥40kg group (Table 1). Most treated pts (92.0%) were 12-17yrs. The majority (91%) of pts were initially dosed with UST every 8 weeks (q8w); at the last known dose, 64% received UST q8w and 22% q4w. Mean (SD) age of initial UST exposure was 15yrs (2.19). Prior IBD surgery was reported in 65.3% pts. The majority of pts (98%) had prior biologic therapy and 72% received ≥2 biologics prior to UST. Overall, 37/150 (24.7%) of pts discontinued UST during follow-up, with a mean (SD) time to discontinuation of 16.7 (17.00) months; 84/150 (56.0%) were exposed to UST for ≥24 months. Rates (events/100 pt-yrs) of AEs were higher in the ≥40kg group (177.62) than in the &lt;40kg group (101.27). Rates of SAEs were slightly lower among the ≥40kg group (25.42) vs &lt;40kg (32.67). There were no SAEs related to infusion or injection site reactions. Rates of serious infections and CD-related hospitalizations were low and similar between groups, and rates of IBD-related surgeries were similar between groups (Figure 1). One malignancy (malignant carcinoid tumor) was reported in a female (18yrs) in the ≥40kg group with a history of prior therapy with vedolizumab, methotrexate, and 6-MP. No deaths or opportunistic infections were reported. Conclusion The safety profile observed for this off-label use of UST in paediatric CD pts in DEVELOP was similar to that of the treated adult population, despite most paediatric pts having prior biologic exposure. No new safety signals are identified in this paediatric population.
Changes in Therapy Are Not Associated With Increased Remission in Patients With Crohn's Disease of the Pouch
Deepak, Parakkal , Beniwal‐Patel, Poonam , Raffals, Laura E. , Dubinsky, Marla C. , Higgins, Peter , Jiang, Yue , Cross, Raymond K. , Long, Millie D. , Deepak, Parakkal , Dubinsky, Marla , Chang, Shannon , Jiang, Yue , Cross, Raymond , Barnes, Edward L , Kayal, Maia , Chang, Sam S. , Herfarth, Hans , Barnes, Edward L.

Mayo Clinic

American Journal of Gastroenterology | November 17, 2023 | Volume: 119 | Issue: 3 | Pages: 584-587

10.14309/ajg.0000000000002599 | PMID 37975591 Get It

INTRODUCTION: There is a paucity of data on the real-world effectiveness of therapies in patients with Crohn's disease of the pouch. METHODS: This was a prospective multicenter study evaluating the primary outcome of remission at 12 months of therapy for Crohn's disease of the pouch. RESULTS: One hundred thirty-four patients were enrolled. Among the 77 patients with symptoms at baseline, 35 (46.7%) achieved remission at 12 months. Of them, 12 (34.3%) changed therapy. There was no significant association between therapy patterns and remission status. DISCUSSION: Approximately 50% with symptoms at enrollment achieved clinical remission at 12 months, most of whom did so without a change in therapy.
S1160 Corticosteroid-Sparing Effect of Upadacitinib in Patients With Moderately-to-Severely Active Crohn’s Disease
Dubinsky, Marla C. , D’Haens, Geert , Lacerda, Ana P. , Dubcenco, Elena, Anyanwu, Samuel I., Garrison, Andrew, Dewit, Olivier , Juillerat, Pascal , Panaccione, Remo , Fujii, Toshimitsu , Anyanwu, Samuel, Doshi, Chirag, Liu, Jianzhong , Loftus, Edward V.

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S887-S888

10.14309/01.ajg.0000954280.83972.54 Get It

S1166 Time to Relapse During Upadacitinib Maintenance Therapy in Patients With Ulcerative Colitis Who Had a Clinical Response to Induction Therapy
Dubinsky, Marla C. , Kujawski, Michelle, Eccleston, Jason , Yao, Xuan , Axelrad, Jordan E. , Loftus, Edward V.

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S892-S893

10.14309/01.ajg.0000954304.38542.d7 Get It

S1120 Vedolizumab Is Effective for the Treatment of Chronic Inflammatory Conditions of the Pouch in a Prospective Multicenter Study
Raffals, Laura H., Qazi, Taha , Beniwal‐Patel, Poonam , Dubinsky, Marla C. , Chang, Shannon, Higgins, Peter , Barr, Jennifer I., Anderson, Chelsea , Long, Millie D. , Barnes, Edward L. , Kayal, Maia , Deepak, Parakkal , Cross, Raymond K. , Herfarth, Hans

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S853-S854

10.14309/01.ajg.0000954120.56351.1a Get It

S909 Efficacy of Upadacitinib in Patients With Crohn’s Disease Activity Index-Based Eligibility Criteria: Post Hoc Analysis of U-EXCEL, U-EXCEED, and U-ENDURE Phase 3 Trials
Lichtenstein, Gary R. , DuVall, Aaron, Chapman, J. Casey, Lacerda, Ana P. , Anyanwu, Samuel I., Garrison, Andrew, Dubinsky, Marla C. , Rubin, David T. , Loftus, Edward V. , Regueiro, Miguel , Anyanwu, Samuel, O’Brien, Daniel J. , Liu, Jianzhong

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S678-S679

10.14309/01.ajg.0000953276.85317.47 Get It